Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec 18;24(1):52.
doi: 10.1186/s12957-025-04131-3.

Impact of microvasculature invasion subtype (MVI vs. LVI) and associated risk factors on survival outcomes in pancreatic cancer after curative surgery

Huangbao Li  1   2 , Chenyang Bian  1   2 , Yuyang Zhou  1   2 , Jiayin Yu  1 , Xiangyi Chen  1 , Fengqing Zhao  3
Affiliations

Impact of microvasculature invasion subtype (MVI vs. LVI) and associated risk factors on survival outcomes in pancreatic cancer after curative surgery

Huangbao Li et al. World J Surg Oncol. .

Abstract

Objective: This study aims to investigate the risk factors associated with microvasculature invasion (MI) in patients with pancreatic cancer and evaluate its prognostic significance.

Methods: A retrospective analysis was conducted on the clinical data of 288 pancreatic cancer patients who underwent radical pancreatectomy between June 2012 and June 2024. The collected data included demographic characteristics, pathological findings, and laboratory results. Logistic regression analysis was performed to identify potential factors associated with the occurrence of MI. The Kaplan-Meier method was employed to estimate disease-free survival (DFS) and overall survival (OS). Univariate and multivariate Cox proportional hazards regression models were applied to assess the impact of various factors on patient prognosis.

Results: Among 288 patients, MI was detected in 93 patients (32.3%). Positive microvasculature biomarkers, positive regional lymph nodes (RNP), poor differentiation grade, and reduced MCV might be independent risk factors for MI. Multivariate Cox regression analysis showed that MI, tumor site, RNP, grade, chemotherapy, chloride (Cl) and thrombin time were independent risk factors for DFS and OS. Among 93 patients with MI, no statistically significant difference in prognosis was observed between the MVI and LVI subtypes.

Conclusion: Positive microvasculature biomarkers, positive RNP, poor histological grade, and reduced MCV levels might serve as independent risk factors for the development of MI. The presence of MI was independent risk factors for DFS and OS. However, no significant prognostic association was observed between the specific origin of invasion (whether MVI or LVI).

Keywords: LVI; MVI; Microvasculature invasion; Pancreatic cancer; Prognostic.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study was performed in accordance with the World Medical Association Declaration of Helsinki and was approved by the Ethics Committee of Cancer Hospital of China Medical University. This study was a retrospective study and all the data used for the final analysis were anonymous. Therefore, the informed consent from the enrolled patients was waived. This study was approved by the Institutional Review Board at the affiliated hospital of Jiaxing University (approval number: LS2021-KY-160). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The Kaplan-Meier survival estimates for disease-free survival and overall survival after surgery grouped by microvasculature invasion. A DFS after surgery, (B) OS after surgery. MI Microvasculature Invasion
Fig. 2
Fig. 2
The Kaplan-Meier survival estimates for DFS and OS after surgery group by origin of microvasculature invasion. A DFS after surgery, (B) OS after surgery. MVI Microvascular Invasion, LVI Micro Lymphovascular Invasion
See this image and copyright information in PMC

References

    1. Uchihara D, Shimajiri S, Harada Y, Kumamoto K, Oe S, Miyagawa K, et al. Long-chain fatty acyl coa synthetase 4 expression in pancreatic cancer: a marker for malignant lesions and prognostic indicator for recurrence. Diagn pathol. 2025;20(1):59. 10.1186/s13000-025-01659-6. - DOI - PMC - PubMed
    1. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10–45. 10.3322/caac.21871. - PMC - PubMed
    1. Stoffel EM, Brand RE, Goggins MP. Cancer: changing epidemiology and new approaches to risk assessment. Early Detect Prev Gastroenterol. 2023;164(5):752–65. 10.1053/j.gastro.2023.02.012. - PMC - PubMed
    1. Ouyang S, Zhang J, Liu F, Jiang Q, Xing W, Chen J. Global research trends and hotspots in prognostic prediction models for pancreatic cancer: a bibliometric analysis. Front Oncol. 2025;15:1588735. 10.3389/fonc.2025.1588735. - DOI - PMC - PubMed
    1. Cai J, Chen H, Lu M, Zhang Y, Lu B, You L, et al. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Cancer Lett. 2021;520:1–11. 10.1016/j.canlet.2021.06.027. - DOI - PubMed

LinkOut - more resources